Refocus Group, Inc.
Limited financial coverage for RFCS.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
Refocus Group, Inc. is a medical technology firm dedicated to the research and creation of therapies for various human vision conditions, particularly presbyopia. A key offering is the VisAbility Micro-Insert System, an experimental medical device currently undergoing clinical evaluations for its application in treating presbyopia affecting both eyes.
- CEO
- J. Michael Judy
- IPO
- 2003
- Employees
- 4
- HQ
- Dallas, TX, US
Price Chart
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.58
- Avg Volume
- 47.40K
Get TickerSpark's AI analysis on RFCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RFCS coverage
Recent articles, reports, and earnings notes.
No research on RFCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RFCS report →Similar companies
Peers in the same neighborhood.